Mr Stephen Fenwick is a Consultant Hepatobiliary and General Surgeon based at the Sefton Suite Hospital and Aintree University Hospital in Liverpool.
Mr Fenwick qualified from Nottingham University and subsequently trained in Nottingham, Derby and Leeds, including a period of research for a Doctor of Medicine thesis, focusing on new treatments for patients with cancers which spread from the bowel to the liver.
Mr Fenwick was appointed as a Consultant Surgeon in 2008. He is also an Honorary Senior Lecturer at the University of Liverpool. He is currently the Clinical Lead of the Liverpool Hepatobiliary Unit, and also the Lead Cancer Clinician within the Hospital. A key development which Mr Fenwick has introduced has been the Advanced Colorectal Cancer Multidisciplinary Team Meeting, bringing together experts to ensure all patients with this condition have access to the best possible treatments.
The Liverpool Hepatobiliary Unit is one of the busiest centres in Europe for the treatment of patients with benign and malignant conditions of the liver and biliary sytem. Each year Mr Fenwick performs in excess of 100 major liver operations including laparoscopic (keyhole) liver resections, as well as around 150 laparoscopic cholecystectomies.
Mr Fenwick holds a number of external positions, including committee membership of specialist associtions, medical advisory board work for two patient charities, and as an independent Specialist Advisor for NICE.
Professor Stephen Devereux is a Consultant Haematologist based at King's College Hospital in London. He is also Professor in Lymphoma Biology at King's College London.
Professor Devereus trained in Haematology at the Royal Free and University College London Hospitals where he also worked as a Senior Lecturer.
Professor Devereux has extensive experience in the diagnosis and treatment of blood cancers with a particular interest in lymphoid malignances and chronic lymphatic leukaemia. He plays an active role in both laboratory and clinical research and directs an internationally competitive team working on the biology of lymphoma at King's College London.
Professor Devereux is Clinical Director of the London South Comprehensive Local Research Network and the South East London Cancer Research Network. He is a medical advisor to the Lymphoma Association and serves on the executive of the UK-CLL forum executive, the NCRN CLL subgroup and the Leukaemia and Lymphoma Research Fund Clinical Trials Committee.
Professor SM Lee is a Professor of Medical Oncology at UCL Cancer Institute and Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and a Consultant Oncologist at UCLH.
Prof Lee studied medicine at St Mary’s Hospital Medical School, University of London, before completing his medical oncology fellowship training at Guy’s and Christie Hospitals. He was a recipient of the American Association for Cancer Research Upjohn Award in 1993, McElwain Prize by the Association of Cancer Physicians in 1994, and completed his postgraduate PhD degree at CRUK Manchester Paterson Institute in 1994. He was appointed a Consultant Medical Oncologist at UCLH in 1998 to specialize in the treatment lung cancer and lymphoma.
Dr Simon Chowdhury is a Consultant Medical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.
Dr Chowdhury was appointed to Guy’s hospital in 2007 to lead the medical oncology group in the treatment of urological cancers.
Dr Chowdhury received his first degree from the University of Cambridge and qualified as a doctor at Guys and St Thomas’ Medical School. He completed his PhD in tumour targeting at University College London. He also trained at St George’s and The Royal Marsden Hospitals. He was a Visiting Fellow at the Dana Farber Cancer Institute in Boston, with which he retains strong links. Between 2000 and 2003. Dr Chowdhury was a Research Fellow for Cancer Research UK.
He is actively involved in clinical trial research into urological cancer, and is a member of the London Kidney Cancer Group which aims to develop further clinical trials in the London area. He is the joint lead for the treatment of urological cancers within the South East London Cancer Network.
He has co-authored over 20 papers in peer-reviewed journals and contributed chapters to six medical texts
Dr Samir Agrawal is a Consultant Haematologist based at St Bartholomew's Hospital in London.
Dr Agrawal qualified initially at the University of Bristol subsequently training at The Royal Marsden Cancer Hospitals and being awarded his PhD (in Immunology) at the University of Paris. A former national junior chess champion, Dr Agrawal today is also Director of The Stem Cell Laboratory (at St Bartholomew's) and Head of Diagnostic Immunophenotyping in addition to his consultant and teaching roles.
Dr Agrawal sits on several bodies reviewing outcomes in haemato-oncology, and was a winner of one of the NHS Innovator Awards in 2006 for his work on the introduction of new diagnostic tests for the diagnosis of human leukaemias. A fluent French speaker, he also runs a specialist translation service preparing clinical and scientific medical articles originally written in French for publication in international English/American medical literature.
Dr Ronald Beaney is a Consultant Clinical Oncologist based at Guys and St. Thomas' NHS Trust in London.
Dr Beaney did his undergraduate training in Scotland followed by posts abroad and in the UK. His oncology training was at the Hammersmith Hospital in London where his MD thesis was on the role of positron emission topography in oncology.
He has been a Consultant Clinical Oncologist attached to Guy's and St Thomas' and King's College Hospitals in London. His major clinical interests lie in tumours of the brain (gliomas) and pelvis (prostate and gynaecological tumours). His current interests are novel drugs for treating tumours and the use of stereotactic radiation, both gamma knife and cyber knife.
Dr Beaney has been on the Faculty Board of the Royal College of Radiologists and an examiner for the same college. He is a Council member of the British neuro-oncology society and a member of the brain tumour working party of the European Organisation for the treatment of Cancer (EORTC) and he is a member of several UK, European and American Cancer Societies and examiner for the Royal College of Radiologists.
Professor Ricky Sharma is a Professor of Clinical Oncology based at University College London.
Prof Sharma graduated in medicine from the University of Cambridge and then trained in general internal medicine, medical oncology and radiation oncology. He completed a PhD on DNA damage repair. Since 2006, he has led a research group at the University of Oxford.
He is the Laboratory Group Leader of the Translational DNA Repair Group at the CRUK/MRC Oxford Institute for Radiation Oncology at the University of Oxford. He is also a Higher Education Funding Council for England (HEFCE) Clinical Senior Lecturer at the University of Oxford, an Honorary Consultant in Clinical Oncology at the Oxford University Hospitals NHS Trust, and a Senior Research Fellow at Harris Manchester College, University of Oxford. His specialisms include radiotherapy, chemotherapy, bowel cancer, liver cancer, and liver-directed therapies.
Dr Sharma has a prominent national and international profile in his field and co-chairs the Early Phase Trials Workstream of the NCRI Clinical Translational Radiotherapy (CTRad) Group and is the Chief Investigator of the NCRN FOXFIRE, a multi-centre, clinical randomised clinical trial testing a new combination of chemotherapy and selective internal radiotherapy in the treatment of liver metastases from colorectal cancer. He is an examiner for Royal College of Radiologists (Clinical Oncology) a member of Faculty Board and a prominent member of several working groups within the college, particularly on interventional oncology and undergraduate education. He also tutors at Harris Manchester College and St Catherine's College, University of Oxford, Dr Sharma is a module leader for postgraduate teaching of radiobiology and oncology and is leading the development of a national mentorship scheme for clinical oncology trainees. He was appointed as Chair of the Teaching Committee of the Oncology Department at the University of Oxford in May 2011.
Dr Sharma is a Fellow of both the Royal College of Physicians and the Royal College of Radiologists.
Dr Rebecca Kristeleit is Clinical Senior Lecturer and Consultant Medical Oncologist at University College London and University College London Hospitals NHS Foundation Trust.
Dr Kristeleit specialises in the treatment of gynaecological cancers.
Dr Kristeleit qualified in medicine from St Andrew’s and Manchester Universities including eight months at the University of Lausanne (Switzerland) on an Erasmus scholarship. Following general medical training in London, Rebecca undertook her medical oncology training at The Royal Marsden Hospital and a CRUK-funded research fellowship at the Institute of Cancer Research. Subsequently, Rebecca spent a year as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital gaining specialist experience in the design and conduct of early phase clinical trials and translational medicine.
She also has a specialist interest in drug development as well and is leading several clinical trials of novel agents relevant to gynecological malignancies including PARP inhibitors.
Dr Paul Nathan is a Consultant Medical Oncologist based at The Mount Vernon Cancer Centre, in Northwood, Middlesex.
Dr Nathan received his first medical degree from Cambridge University and qualified in medicine at University College London, both achieved after earlier degrees (including a PhD) specialising in immunology. He was a Fulbright Scholar and carried out his post-doctoral research at the Pittsburgh Cancer Institute in the US. He initially pursued cancer research in academia and in the pharmaceutical industry before finally deciding to pursue a clinical career.
Dr Nathan has a specialist interest in the treatment of renal cell carcinoma (kidney cancer) and melanoma (both uveal and cutaneous). He also has an interest in Merkel Cell Carcinoma.
He is first author of the UK guidelines for the systemic treatment of renal cell carcinoma, a member of the National Cancer Research Institute groups for both renal carcinoma and melanoma and is secretary of the UK Melanoma Study Group. He also is a member of the panel currently reviewing the national melanoma guidelines.